Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Krystal Biotech ( (KRYS) ) has issued an update.
Krystal Biotech announced positive initial clinical results from its KYANITE-1 study on inhaled KB707 for lung tumors, particularly showing monotherapy efficacy in advanced non-small cell lung cancer (NSCLC) patients. The study demonstrated a 27% objective response rate and a 73% disease control rate, with the potential to enhance Krystal’s positioning in cancer treatment. The company plans to expand the study to test KB707 in combination with other cancer therapies, aiming for broader application and impact.
More about Krystal Biotech
Krystal Biotech, Inc. is a commercial-stage biotechnology company based in Pittsburgh, Pennsylvania. It focuses on the discovery, development, and commercialization of genetic medicines to address diseases with high unmet medical needs, spanning areas like respiratory, oncology, dermatology, ophthalmology, and aesthetics. The company’s first commercial product, VYJUVEK®, is a notable redosable gene therapy approved by the FDA for treating dystrophic epidermolysis bullosa.
YTD Price Performance: 35.10%
Average Trading Volume: 233,627
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $4.86B
See more data about KRYS stock on TipRanks’ Stock Analysis page.
